Atriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE) on September 8, 2023. Pursuant to the Transaction, Biocure Technology Inc. will issue common shares in its capital to the shareholders in the capital of Atriva on the basis of a proposed exchange ratio such that, following the closing of the Transaction, on a fully diluted basis, approximately 75% of the securities of the Resulting Issuer will be held by current Atriva securityholders, together with subscribers in a concurrent financing, and approximately 25% of the securities of the Resulting Issuer will be held by current CURE shareholders. the transaction is subject to the completion of satisfactory due diligence, the parties entering into a definitive agreement with respect to the Transaction on or before November 30, 2023, the completion of a private placement by Atriva or CURE and the approval of the shareholders of the Company and Atriva, and the approval of the CSE and other applicable regulatory authorities.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.015 CAD | -25.00% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 1.03M | |
+7.81% | 2.86B | |
+41.28% | 2.32B | |
+10.02% | 1.87B | |
+41.19% | 1.56B | |
-20.25% | 702M | |
-3.09% | 306M | |
+17.98% | 108M | |
-26.67% | 62.46M |
- Stock Market
- Equities
- CURE Stock
- News Biocure Technology Inc.
- Atriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc..